# FDA Inspection 1269601 - GlaxoSmithKline LLC - October 21, 2025

Source: https://www.keypedia.com/records/fda_inspections/glaxosmithkline-llc/20db5d03-0b64-4e2b-ad06-3dc93061d3e1
Source feed: FDA_Inspections

> FDA Inspection 1269601 for GlaxoSmithKline LLC on October 21, 2025. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1269601
- Company Name: GlaxoSmithKline LLC
- Inspection Date: 2025-10-21
- Classification: No Action Indicated (NAI)
- Project Area: Bioresearch Monitoring
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 1269601 - 2025-10-21](https://www.keypedia.com/records/fda_inspections/glaxosmithkline-llc/38c523f3-e26b-4e0f-94a7-9a28970204ee)
- [FDA Inspection 1253764 - 2024-11-22](https://www.keypedia.com/records/fda_inspections/glaxosmithkline-llc/25ed9c8b-c8fa-4308-accb-89ef66b689be)
- [FDA Inspection 1253764 - 2024-11-22](https://www.keypedia.com/records/fda_inspections/glaxosmithkline-llc/ef15e684-98dc-40b7-a199-0bab72b09bfc)
- [FDA Inspection 1187325 - 2022-10-24](https://www.keypedia.com/records/fda_inspections/glaxosmithkline-llc/b6359036-ed93-4a46-9299-a165e4e3f641)
- [FDA Inspection 1180594 - 2022-08-12](https://www.keypedia.com/records/fda_inspections/glaxosmithkline-llc/c7911d19-24da-490e-a71d-1954208eaf86)

Company: https://www.keypedia.com/companies/glaxosmithkline-llc/b0586c5b-ed04-498a-befc-515b46a93b3a

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c